Human Intestinal Amino Acid Absorption and the Role of a Local (Renin)-Angiotensin System (RAS)

NCT01252368 | Completed

• 1 other identifier: EK-1744
• Study Type: observational
• Target: 48
• Locations: 1 country
• Sites: 1

Brief Summary

Aim of this trial is to investigate the expression and localisation of different amino acid transporters and their regulatory proteins derived from the regulatory proteins of the local renin angiotensin system (RAS) in the intestine. This is investigated on one hand in patients who do not take any drugs interfering with RAS. On the other hand expression analysis is done in patients taking daily RAS-active drugs, like ACE inhibitors or sartanes. After obtaining informed consent of patients attending the hospital for clarification of gastrointestinal symptoms by gastroduodenoscopy or colonoscopy, 2 biopsies (in addition to biopsies needed for clinical diagnostics) will be taken from each duodenum, jejunum, ileum and descending colon. Biopsies are investigated anonymously at the Institute of Physiology of the University of Zurich. The mRNA content of amino acid transporters and regulatory proteins, respectively, in the biopsies is analyzed by quantitative PCR. Transport proteins are in addition analyzed with immunohistochemistry. Furthermore amino acid concentration in plasma and urine samples are analyzed by HPLC. From plasma and serum samples RAS parameters like renin, aldosterone, ACE and angiotensin(1-7) are measured.

Conditions

Healthy Participants; Hypertension

Study Arms (2)

RAS active drugs

ACE inhibitors and sartanes

Biological: hypertension

healthy participants

Interventions

hypertension BIOLOGICAL

patients taking daily ACE inhibitors or sartanes

RAS active drugs

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Probability Sample

Study Population

Patients attending the hospital for clarification of gastrointestinal symptoms by gastroduodenoscopy or colonoscopy

You may qualify if:

• Men and women aged 18-80 years
• BMI 18-35 kg/m2
• Group 1: patients taking daily RAS-active drugs, like ACE inhibitors or sartanes (treatment indication outside of this study)
• Group 2: no therapy with RAS-active drugs, like ACE inhibitors or sartanes Gastroduodenoscopy and/or colonoscopy with a treatment indication outside of this study
• Informed consent

You may not qualify if:

• Status after operations of the gastrointestinal tract (except uncomplicated appendectomy or inguinal hernia repair)
• Patients with malignant diseases
• Severe acute or chronic diseases which require treatment (e.g. renal replacement therapy)
• Patients with increased bleeding risk (e.g. oral anticoagulation, coagulopathy)
• Drug or alcohol abuse
• Mental disorders which limits the ability to fulfil all study requirements

Sponsors & Collaborators

• University of Zurich: lead

Study Sites (1)

University Hospital Zurich, Gastroenterology and Hepatology

Zurich, Canton of Zurich, 8091, Switzerland

Location

MeSH Terms

Conditions

Hypertension

Condition Hierarchy (Ancestors)

Vascular Diseases; Cardiovascular Diseases

Study Officials

• Werner Schwizer, Professor MD

  University Hospital Zurich, Gastroenterology and Hepatology

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 30, 2010
• First Posted: December 3, 2010
• Study Start: December 1, 2009
• Study Completion: May 1, 2011
• Last Updated: November 29, 2012

Record last verified: 2012-11

Locations

CH (1)